204 related articles for article (PubMed ID: 24098552)
1. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Jiang YH; Kuo HC
PLoS One; 2013; 8(10):e76706. PubMed ID: 24098552
[TBL] [Abstract][Full Text] [Related]
2. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
3. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
[TBL] [Abstract][Full Text] [Related]
4. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
6. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
7. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
Tubaro A; De Nunzio C
BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
[No Abstract] [Full Text] [Related]
8. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
[TBL] [Abstract][Full Text] [Related]
9. Overactive bladder: recognition requires vigilance for symptoms.
Rosenberg MT; Newman DK; Tallman CT; Page SA
Cleve Clin J Med; 2007 May; 74 Suppl 3():S21-9. PubMed ID: 17546830
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
11. Fesoterodine fumarate.
Gomelsky A; Dmochowski RR
Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
[TBL] [Abstract][Full Text] [Related]
12. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
Herschorn S; Kaplan SA; Sun F; Ntanios F
Urology; 2014 May; 83(5):1023-9. PubMed ID: 24582119
[TBL] [Abstract][Full Text] [Related]
13. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
14. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
16. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
Rogers R; Bachmann G; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Nov; 19(11):1551-7. PubMed ID: 18685795
[TBL] [Abstract][Full Text] [Related]
19. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.
Tang H; Chen J; Wang Y; Yu T; Guo C; Liao X
Urol J; 2014 Sep; 11(4):1800-5. PubMed ID: 25194079
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]